Immunic, Inc. to Participate in Major Conferences
Immunic, Inc. (Nasdaq: IMUX), a pioneering biotechnology firm focused on developing small molecule therapies aimed at chronic inflammatory and autoimmune diseases, recently shared its schedule for participation in significant investor and scientific conferences during September. This showcases the company's commitment to advancing its innovative treatment solutions.
Upcoming Conferences and Presentations
During the month of September, Immunic is set to feature its latest developments at the following notable conferences:
- H.C. Wainwright 27th Annual Global Investment Conference - September 8-10
- 2025 Leerink Partners Biopharma Summit - September 17-19
- 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - September 24-26
Jason Tardio, President and COO of Immunic, will deliver an overview of the company. Interested parties may access the on-demand presentation starting September 5 at 7:00 AM ET via the H.C. Wainwright Conference Portal. Tardio, along with Daniel Vitt, Ph.D., CEO, and Jessica Breu, VP of Investor Relations, will also hold one-on-one meetings with investors at the conference in New York. For meeting scheduling details, participants can visit the conference website.
Here, Dr. Vitt will engage in discussions around the company’s advancements and future directions.
Members from the various Immunic teams, including management and medical staff, will showcase the company's contributions at this vital conference. Key data regarding their innovative asset, vidofludimus calcium (IMU-838), will be communicated through oral and poster presentations, further highlighting Immunic’s role in advancing therapeutic understanding in multiple sclerosis.
Key Presentation Details at ECTRIMS
At ECTRIMS, Immunic will present data from important studies:
- Oral Presentation: Efficacy and Safety of Vidofludimus Calcium, a Novel Nurr1 Activator and Selective DHODH Inhibitor, in Progressive Multiple Sclerosis: Data from the Phase 2 CALLIPER Trial
- Presenting Author: Robert J. Fox, M.D., from the Cleveland Clinic, will lead this session.
- Abstract Number: ECTRIMS25-1404
- Session Details: This presentation is scheduled for September 24 at 2:35 PM CEST.
Late Breaking and Poster Presentations
In addition to the oral sessions, Immunic will feature late-breaking posters covering vital research:
- Poster Presentation: Efficacy and Safety of Vidofludimus Calcium in Primary Progressive Multiple Sclerosis: Phase 2 CALLIPER Trial
- Abstract Number: IMS25-LBA-317
- Time: Scheduled for September 24 from 4:30-6:30 PM CEST.
Innovations by Immunic, Inc.
Immunic, Inc. stands at the forefront of biotechnology, channeling efforts into their lead product vidofludimus calcium (IMU-838). Presently in phase 3 clinical trials for relapsing multiple sclerosis, this innovative drug is distinguished by its dual mechanism of action: acting as a nuclear receptor-related 1 (Nurr1) activator while also inhibiting dihydroorotate dehydrogenase (DHODH). As a result, it not only displays neuroprotective capabilities but also anti-viral and anti-inflammatory properties, establishing itself as a significant advancement in therapeutic strategies.
Moreover, developing therapies such as IMU-856, targeting Sirtuin 6 (SIRT6), seeks to enhance intestinal barrier function, which holds promise for gastrointestinal diseases such as celiac disease and inflammatory bowel diseases. Another exciting molecule, IMU-381, is currently in preclinical evaluation and aims to cater specifically to gastrointestinal disorders.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is committed to developing a pipeline of innovative orally administered small molecule therapies tackling chronic inflammatory and autoimmune diseases. With a firm foothold in the clinical landscape, the company anticipates crucial top-line data from its lead program by the end of 2026. For more detailed insights, interested parties may visit the company’s website.
Frequently Asked Questions
What events will Immunic, Inc. participate in during September?
Immunic, Inc. will participate in the H.C. Wainwright Conference, the Leerink Partners Biopharma Summit, and the ECTRIMS conference.
What is Immunic’s lead product?
The lead product is vidofludimus calcium (IMU-838), which focuses on treating relapsing multiple sclerosis.
Where can I find detailed research presentations from Immunic?
All presentations will be available on Immunic's website under the 'Events and Presentations' section following the conferences.
Who will present at the ECTRIMS conference?
Robert J. Fox, M.D., will present crucial data regarding vidofludimus calcium’s efficacy and safety.
What role does SIRT6 play in Immunic’s developmental pipeline?
SIRT6 is targeted by IMU-856, which aims to restore intestinal function and address various gastrointestinal disorders.
